摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 298680-38-3

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
298680-38-3
化学式
C33H32N4O5
mdl
——
分子量
564.63
InChiKey
IZGVQNHSBPKKRO-RIHQVDFKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    758.8±70.0 °C(Predicted)
  • 密度:
    1.31±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.34
  • 重原子数:
    42.0
  • 可旋转键数:
    6.0
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    95.13
  • 氢给体数:
    0.0
  • 氢受体数:
    8.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    以96的产率得到9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one
    参考文献:
    名称:
    Derivatives of pyrimido[6,1-a]isoquinolin-4-one
    摘要:
    通式(I)的化合物,其中R1和R2分别独立地表示C1-6烷基或C2-7酰基基团;R5表示氢原子或C1-3烷基,C2-3烯基或C2-3炔基基团;R6表示氢原子或C1-6烷基,C2-6烯基,C2-6炔基,氨基,C1-6烷基氨基,二(C1-6)烷基氨基或C2-7酰氨基基团,R7和R8分别独立地表示氢或卤素原子或羟基,三氟甲基,C1-6烷基,C2-6烯基,C2-6炔基,C2-7酰,C1-6烷硫基,C1-6烷氧基,C3-6环烷基;R9表示氢或卤素原子或羟基,三氟甲基,C1-6烷基,C2-6烯基,C2-6炔基,C2-7酰,C1-6烷硫基,C1-6烷氧基或C3-6环烷基;X表示OCH2或CR3R4基团,其中R3和R4分别独立地表示氢原子或C1-3烷基;R10和R11分别独立地表示氢原子,C1-3烷基,C3-6环烷基或苯基;y表示氧原子或CHNO2,NCN,NH或NNO2基团,n为2到4的整数;或其盐;对于治疗哮喘等呼吸系统疾病有用。本发明的化合物比已知的trequinsin(9,10-二甲氧基-3-甲基-2-间苯基亚胺基-2,3,6,7-四氢-4H-嘧啶并[6,1-a]-异喹啉-4-酮)具有更长的作用时间,并且不具有trequinsin的非常苦的味道。
    公开号:
    US07105663B2
  • 作为产物:
    描述:
    2,4,6-三甲基苯胺potassium carbonate 、 sodium iodide 作用下, 以 氯苯异丙醇甲苯 为溶剂, 反应 44.0h, 生成
    参考文献:
    名称:
    SOLID STATE FORMS OF ENSIFENTRINE
    摘要:
    The present invention relates to solid state forms of Ensifentrine and methods for preparation, use and isolation of such compounds and novel process for the preparation of Ensifentrine. The present invention further relates to an improved, cost effective and industrially viable process for preparation of Ensifentrine.
    公开号:
    WO2024127413A1
点击查看最新优质反应信息

文献信息

  • Derivatives of pyrimido[6.1-a]isoquinolin-4-one
    申请人:——
    公开号:US20030036542A1
    公开(公告)日:2003-02-20
    The invention provides compounds or salts thereof of the general formula (I): 1 wherein each of R 1 and RX independently represents a C 1-6 alkyl or C 2-7 acyl group; X represents OCH 2 or a group CR 3 R 4 ; wherein each of R 3 or R 4 independently represents a hydrogen atom or a C 1-3 alkyl group; R 5 represents a hydrogen atom or a C 1-3 alkyl, C 2-3 alkenyl or C 2-3 alkynyl group; R 6 represents a hydrogen atom or a C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, amino, C 1-6 alkylamino, di(C 1-6 ) alkylamino or C 2-7 acylamino group; each of R 7 and R 8 independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-7 acyl, C 1-6 alkylthio, C 1-6 alkoxy, C 3-6 cycloalkyl; and R 9 represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-7 acyl, C 1-6 alkylthio, C 1-6 alkoxy or C 3-6 cycloalkyl group. The compounds or salts thereof are useful for treatment of respiratory disorders such as asthma. Compounds of the invention have a longer duration of action than the known compound trequinsin (9,10-dimethoxy-3 methyl-2-mesitylimino-2,3,6,7-tetrahydro- 4 -H-pyrimido[6,1-a]isoquinolin-4-one).
    该发明提供了通式(I)的化合物或其盐: 其中,R1和RX分别独立表示C1-6烷基或C2-7酰基;X表示OCH2或CR3R4基团;R3或R4分别独立表示氢原子或C1-3烷基;R5表示氢原子或C1-3烷基、C2-3烯基或C2-3炔基;R6表示氢原子或C1-6烷基、C2-6烯基、C2-6炔基、基、C1-6烷基基、二(C1-6)烷基基或C2-7酰基;R7和R8分别独立表示氢或卤素原子、羟基、三甲基、C1-6烷基、C2-6烯基、C2-6炔基、C2-7酰基、C1-6烷基基、C1-6烷氧基、C3-6环烷基;R9表示氢或卤素原子、羟基、三甲基、C1-6烷基、C2-6烯基、C2-6炔基、C2-7酰基、C1-6烷基基、C1-6烷氧基或C3-6环烷基。该化合物或其盐可用于治疗哮喘等呼吸系统疾病。该发明的化合物比已知的化合物特雷昆辛(9,10-二甲氧基-3-甲基-2-间二甲苯亚基-2,3,6,7-四氢-4H-嘧啶并[6,1-a]异喹啉-4-酮)具有更长的作用持续时间。
  • [EN] DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE<br/>[FR] DERIVES DE PYRIMIDO [6,1-A] ISOQUINOLEIN-4-ONE ET LEUR UTILISATION EN MEDECINE
    申请人:VANGUARD MEDICA LTD
    公开号:WO2000058308A1
    公开(公告)日:2000-10-05
    Compounds of general formula (I) wherein each of R?1 and R2¿ independently represents a C¿1-6? alkyl or C2-7 acyl group; R?5¿ represents a hydrogen atom or a C¿1-3? alkyl, C2-3 alkenyl or C2-3 alkynyl group; R?6¿ represents a hydrogen atom or a C¿1-6? alkyl, C2-6 alkenyl, C2-6 alkynyl, amino, C1-6 alkylamino, di(C1-6) alkylamino or C2-7 acylamino group; each of R?7 and R8¿ independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C¿1-6? alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-7 acyl, C1-6 alkythio, C1-6 alkoxy, C3-6 cycloalkyl; and R?9¿ represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C¿1-6? alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-7 acyl, C1-6 alkythio, C1-6 alkoxy or C3-6 cycloalkyl group; X represents OCH2 or a group CR?3R4¿, wherein each of R?3 and R4¿ independently represents a hydrogen atom or a C¿1-3? alkyl group; each of R?10 and R11¿ independently represents a hydrogen atom, a C¿1-3? alkyl, C3-6 cycloalkyl or phenyl group; y represents an oxygen atom or a group CHNO2, NCN, NH or NNO2, n is an integer from 2 to 4; or a salt thereof; are useful for treatment of respiratory disorders such as asthma. Compounds of the invention have a longer duration of action than the known compound trequinsin (9, 10-dimethoxy-3-methyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one) and do not have trequinsin's very bitter taste.
    通式(I)的化合物其中R1和R2分别独立地表示C1-6烷基或C2-7酰基基团;R5表示氢原子或C1-3烷基,C2-3烯基或C2-3炔基基团;R6表示氢原子或C1-6烷基,C2-6烯基,C2-6炔基,基,C1-6烷基基,双(C1-6)烷基基或C2-7酰基基基团;R7和R8分别独立地表示氢或卤原子或羟基,三甲基,C1-6烷基,C2-6烯基,C2-6炔基,C2-7酰基,C1-6烷基,C1-6烷氧基,C3-6环烷基;R9表示氢或卤原子或羟基,三甲基,C1-6烷基,C2-6烯基,C2-6炔基,C2-7酰基,C1-6烷基,C1-6烷氧基或C3-6环烷基基团;X表示OCH2或CR3R4基团,其中R3和R4分别独立地表示氢原子或C1-3烷基基团;R10和R11分别独立地表示氢原子,C1-3烷基,C3-6环烷基或苯基;y表示氧原子或CHNO2,NCN,NH或NNO2基团,n为2到4的整数;或其盐;用于治疗哮喘等呼吸系统疾病。与已知化合物trequinsin(9,10-二甲氧基-3-甲基-2-二苯基亚胺-2,3,6,7-四氢-4H-嘧啶[6,1-a]异喹啉-4-酮)相比,本发明化合物具有更长的作用时间,并且不具有trequinsin非常苦的味道。
  • Derivatives of pyrimido[6, 1-A]isoquinolin-4-one
    申请人:Oxford Alexander William
    公开号:US20080206163A1
    公开(公告)日:2008-08-28
    Compounds of general formula (I) wherein each of R 1 and R 2 independently represents a C 1-6 alkyl or C 2-7 acyl group; R 5 represents a hydrogen atom or a C 1-3 alkyl, C 2-3 alkenyl or C 2-3 alkynyl group; R 6 represents a hydrogen atom or a C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, amino, C 1-6 alkylamino, di(C 1-6 ) alkylamino or C 2-7 acylamino group; each of R 7 and R 8 independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-7 acyl, C 1-6 alkythio, C 1-6 alkoxy, C 3-6 cycloalkyl; and R 9 represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-7 acyl, C 1-6 alkythio, C 1-6 alkoxy or C 3-6 cycloalkyl group; X represents OCH 2 or a group CR 3 R 4 , wherein each of R 3 and R 4 independently represents a hydrogen atom or a C 1-3 alkyl group; each of R 10 and R 11 independently represents a hydrogen atom, a C 1-3 alkyl, C 3-6 cycloalkyl or phenyl group; y represents an oxygen atom or a group CHNO 2 , NCN, NH or NNO 2 , n is an integer from 2 to 4; or a salt thereof; are useful for treatment of respiratory disorders such as asthma. Compounds of the invention have a longer duration of action than the known compound trequinsin (9,10-dimethoxy-3-methyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one) and do not have trequinsin's very bitter taste.
    通式(I)的化合物,其中R1和R2各自独立地表示C1-6烷基或C2-7酰基基团;R5表示氢原子或C1-3烷基,C2-3烯基或C2-3炔基基团;R6表示氢原子或C1-6烷基,C2-6烯基,C2-6炔基,基,C1-6烷基基,二(C1-6)烷基基或C2-7酰胺基团;R7和R8各自独立地表示氢或卤原子,或羟基,三甲基,C1-6烷基,C2-6烯基,C2-6炔基,C2-7酰基,C1-6烷基,C1-6烷氧基,C3-6环烷基;R9表示氢或卤原子,或羟基,三甲基,C1-6烷基,C2-6烯基,C2-6炔基,C2-7酰基,C1-6烷基,C1-6烷氧基或C3-6环烷基;X表示OCH2或CR3R4基团,其中R3和R4各自独立地表示氢原子或C1-3烷基;R10和R11各自独立地表示氢原子,C1-3烷基,C3-6环烷基或苯基;y表示氧原子或CHNO2,NCN,NH或NNO2基团,n为2到4的整数;或其盐;可用于治疗哮喘等呼吸系统疾病。本发明的化合物比已知化合物特雷昆辛(9,10-二甲氧基-3-甲基-2-间苯基亚胺-2,3,6,7-四氢-4H-嘧啶[6,1-a]异喹啉-4-酮)具有更长的作用时间,并且不具有特雷昆辛的非常苦涩的味道。
  • DERIVATIVES OF PYRIMIDO [6,1-A] ISOQUINOLIN-4-ONE
    申请人:Oxford Alexander William
    公开号:US20120302533A1
    公开(公告)日:2012-11-29
    The present invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their application as inhibitors of phosphodiesterase (PDE) isoenzymes. More particularly the invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their use in medicine for example as bronchodilators with anti-inflammatory properties.
    本发明涉及嘌呤并[6,1-a]异喹啉-4-酮的衍生物及其作为磷酸二酯酶(PDE)同工酶抑制剂的应用。更具体地,本发明涉及嘌呤并[6,1-a]异喹啉-4-酮的衍生物及其在医学上的应用,例如作为具有抗炎作用的支气管扩张剂。
  • Compound and process
    申请人:VERONA PHARMA PLC
    公开号:US10710998B2
    公开(公告)日:2020-07-14
    The present invention relates to a novel nitrile derivative of a pyrimido[6,1-a]isoquinolin-4-one compound of formula (A). The invention further relates to a process for producing a compound of formula (A). The invention also relates to a process which comprises reducing a compound of formula (A). Compounds of the invention are useful in the production of compounds such as RPL554.
    本发明涉及一种新型的式(A)嘧啶并[6,1-a]异喹啉-4-酮化合物的腈衍生物。本发明还涉及一种生产式(A)化合物的工艺。本发明还涉及一种包括还原式(A)化合物的工艺。本发明化合物可用于生产 RPL554 等化合物。
查看更多

同类化合物

(1Z,3Z)-1,3-双[[((4S)-4,5-二氢-4-苯基-2-恶唑基]亚甲基]-2,3-二氢-5,6-二甲基-1H-异吲哚 鲁拉西酮杂质33 鲁拉西酮杂质07 马吲哚 颜料黄110 顺式-六氢异吲哚盐酸盐 顺式-2-[(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)甲基]-N-乙基-1-苯基环丙烷甲酰胺 顺式-2,3,3a,4,7,7a-六氢-1H-异吲哚 顺-N-(4-氯丁烯基)邻苯二甲酰亚胺 降莰烷-2,3-二甲酰亚胺 降冰片烯-2,3-二羧基亚胺基对硝基苄基碳酸酯 降冰片烯-2,3-二羧基亚胺基叔丁基碳酸酯 阿胍诺定 阿普斯特降解杂质 阿普斯特杂质FA 阿普斯特杂质68 阿普斯特杂质29 阿普斯特杂质27 阿普斯特杂质26 阿普斯特杂质19 阿普斯特杂质08 阿普斯特杂质03 阿普斯特杂质 阿普斯特二聚体杂质 阿普斯特 防焦剂MTP 铝酞菁 铁(II)1,2,3,4,8,9,10,11,15,16,17,18,22,23,24,25-十六氟-29H,31H-酞菁 铁(II)2,9,16,23-四氨基酞菁 钠S-(2-{[2-(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙基]氨基}乙基)氢硫代磷酸酯 酞酰亚胺-15N钾盐 酞菁锡 酞菁二氯化硅 酞菁 单氯化镓(III) 盐 酞美普林 邻苯二甲酸亚胺 邻苯二甲酰基氨氯地平 邻苯二甲酰亚胺,N-((吗啉)甲基) 邻苯二甲酰亚胺阴离子 邻苯二甲酰亚胺钾盐 邻苯二甲酰亚胺钠盐 邻苯二甲酰亚胺观盐 邻苯二亚胺甲基磷酸二乙酯 那伏莫德 过氧化氢,2,5-二氢-5-苯基-3H-咪唑并[2,1-a]异吲哚-5-基 达格吡酮 诺非卡尼 螺[环丙烷-1,1'-异二氢吲哚]-3'-酮 螺[异吲哚啉-1,4'-哌啶]-3-酮盐酸盐 葡聚糖凝胶G-25